135 related articles for article (PubMed ID: 34728553)
21. Functional analysis of the relationship between the neurofibromatosis 2 tumor suppressor and its binding partner, hepatocyte growth factor-regulated tyrosine kinase substrate.
Sun CX; Haipek C; Scoles DR; Pulst SM; Giovannini M; Komada M; Gutmann DH
Hum Mol Genet; 2002 Dec; 11(25):3167-78. PubMed ID: 12444101
[TBL] [Abstract][Full Text] [Related]
22. Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types.
James MF; Stivison E; Beauchamp R; Han S; Li H; Wallace MR; Gusella JF; Stemmer-Rachamimov AO; Ramesh V
Mol Cancer Res; 2012 May; 10(5):649-59. PubMed ID: 22426462
[TBL] [Abstract][Full Text] [Related]
23. CUDC907, a dual phosphoinositide-3 kinase/histone deacetylase inhibitor, promotes apoptosis of NF2 Schwannoma cells.
Huegel J; Dinh CT; Martinelli M; Bracho O; Rosario R; Hardin H; Estivill M; Griswold A; Gultekin S; Liu XZ; Fernandez-Valle C
Oncotarget; 2022; 13():890-904. PubMed ID: 35875610
[TBL] [Abstract][Full Text] [Related]
24. Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma.
Maze EA; Agit B; Reeves S; Hilton DA; Parkinson DB; Laraba L; Ercolano E; Kurian KM; Hanemann CO; Belshaw RD; Ammoun S
Cancer Res; 2022 Jan; 82(2):235-247. PubMed ID: 34853069
[TBL] [Abstract][Full Text] [Related]
25. The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours.
Ammoun S; Schmid MC; Zhou L; Hilton DA; Barczyk M; Hanemann CO
Mol Oncol; 2015 Jan; 9(1):236-48. PubMed ID: 25217104
[TBL] [Abstract][Full Text] [Related]
26. A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor.
Hirokawa Y; Tikoo A; Huynh J; Utermark T; Hanemann CO; Giovannini M; Xiao GH; Testa JR; Wood J; Maruta H
Cancer J; 2004; 10(1):20-6. PubMed ID: 15000491
[TBL] [Abstract][Full Text] [Related]
27. Functional analysis of neurofibromatosis 2 (NF2) missense mutations.
Gutmann DH; Hirbe AC; Haipek CA
Hum Mol Genet; 2001 Jul; 10(14):1519-29. PubMed ID: 11448944
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of SIRT2 in merlin/NF2-mutant Schwann cells triggers necrosis.
Petrilli A; Bott M; Fernández-Valle C
Oncotarget; 2013 Dec; 4(12):2354-65. PubMed ID: 24259290
[TBL] [Abstract][Full Text] [Related]
29. Neurofibromatosis.
McClatchey AI
Annu Rev Pathol; 2007; 2():191-216. PubMed ID: 18039098
[TBL] [Abstract][Full Text] [Related]
30. Proteasomal pathway inhibition as a potential therapy for NF2-associated meningioma and schwannoma.
Bhattacharyya S; Oblinger JL; Beauchamp RL; Yin Z; Erdin S; Koundinya P; Ware AD; Ferrer M; Jordan JT; Plotkin SR; Xu L; Chang LS; Ramesh V
Neuro Oncol; 2023 Sep; 25(9):1617-1630. PubMed ID: 36806881
[TBL] [Abstract][Full Text] [Related]
31. Loss of the NF2 gene and merlin occur by the tumorlet stage of schwannoma development in neurofibromatosis 2.
Stemmer-Rachamimov AO; Ino Y; Lim ZY; Jacoby LB; MacCollin M; Gusella JF; Ramesh V; Louis DN
J Neuropathol Exp Neurol; 1998 Dec; 57(12):1164-7. PubMed ID: 9862639
[TBL] [Abstract][Full Text] [Related]
32. An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis.
Stepanova DS; Semenova G; Kuo YM; Andrews AJ; Ammoun S; Hanemann CO; Chernoff J
Cancer Res; 2017 Sep; 77(18):5026-5038. PubMed ID: 28729415
[TBL] [Abstract][Full Text] [Related]
33. Truncated NF2 proteins are not detected in meningiomas and schwannomas.
Den Bakker MA; van Tilborg AA; Kros JM; Zwarthoff EC
Neuropathology; 2001 Sep; 21(3):168-73. PubMed ID: 11666013
[TBL] [Abstract][Full Text] [Related]
34. Merlin, the NF2 gene product.
Pećina-Šlaus N
Pathol Oncol Res; 2013 Jul; 19(3):365-73. PubMed ID: 23666797
[TBL] [Abstract][Full Text] [Related]
35. The importance of nerve microenvironment for schwannoma development.
Schulz A; Büttner R; Hagel C; Baader SL; Kluwe L; Salamon J; Mautner VF; Mindos T; Parkinson DB; Gehlhausen JR; Clapp DW; Morrison H
Acta Neuropathol; 2016 Aug; 132(2):289-307. PubMed ID: 27236462
[TBL] [Abstract][Full Text] [Related]
36. FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas.
Licciulli S; Maksimoska J; Zhou C; Troutman S; Kota S; Liu Q; Duron S; Campbell D; Chernoff J; Field J; Marmorstein R; Kissil JL
J Biol Chem; 2013 Oct; 288(40):29105-14. PubMed ID: 23960073
[TBL] [Abstract][Full Text] [Related]
37. Altered adhesive structures and their relation to RhoGTPase activation in merlin-deficient Schwannoma.
Flaiz C; Ammoun S; Biebl A; Hanemann CO
Brain Pathol; 2009 Jan; 19(1):27-38. PubMed ID: 18445079
[TBL] [Abstract][Full Text] [Related]
38. Rac1 is required for Prkar1a-mediated Nf2 suppression in Schwann cell tumors.
Manchanda PK; Jones GN; Lee AA; Pringle DR; Zhang M; Yu L; La Perle KM; Kirschner LS
Oncogene; 2013 Jul; 32(30):3491-9. PubMed ID: 23045281
[TBL] [Abstract][Full Text] [Related]
39. Calpain-dependent proteolysis of NF2 protein: involvement in schwannomas and meningiomas.
Kimura Y; Saya H; Nakao M
Neuropathology; 2000 Sep; 20(3):153-60. PubMed ID: 11132929
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.
Laraba L; Hillson L; de Guibert JG; Hewitt A; Jaques MR; Tang TT; Post L; Ercolano E; Rai G; Yang SM; Jagger DJ; Woznica W; Edwards P; Shivane AG; Hanemann CO; Parkinson DB
Brain; 2023 Apr; 146(4):1697-1713. PubMed ID: 36148553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
